Todd Collin M 4

What Happened Todd Collin M, Senior Vice President, Strategy and Business Development at Odyssey Therapeutics (ODTX), was granted a derivative award of 93,904 shares (reported as $0.00 acquisition) on 2026-05-07. The award is a stock option grant (derivative) rather than an open-market purchase or sale — no shares were sold or exercised in this filing.

Key Details

• Transaction date: 2026-05-07; Filing date (Form 4): 2026-05-11.
• Grant: 93,904 derivative shares (option award) with an acquisition price of $0.00 as reported.
• Vesting: Option vests in 48 equal monthly installments; first vesting on June 7, 2026, subject to continued service (per footnote).
• Shares owned after the transaction: not specified in the provided filing data.
• Timeliness: Filing occurred four days after the reported transaction; insiders are generally required to file Form 4 within two business days, so this appears later than the standard deadline.

Context This was a compensation grant (option award) for a senior executive, not a market purchase or sale. Grants are common for employee incentives and do not on their own indicate immediate buying or selling of stock; the options will vest over time and may only lead to ownership if/when vested options are exercised.